Published in J Med Microbiol on November 15, 2012
Aspergillus felis sp. nov., an emerging agent of invasive aspergillosis in humans, cats, and dogs. PLoS One (2013) 1.59
Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob Agents Chemother (2013) 1.08
Aspergillus fumigatus and related species. Cold Spring Harb Perspect Med (2014) 0.85
An alternative host model of a mixed fungal infection by azole susceptible and resistant Aspergillus spp strains. Virulence (2015) 0.83
Extrolites of Aspergillus fumigatus and Other Pathogenic Species in Aspergillus Section Fumigati. Front Microbiol (2016) 0.81
Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification. Eur J Clin Microbiol Infect Dis (2015) 0.81
Aspergillus fumigatus-Related Species in Clinical Practice. Front Microbiol (2016) 0.81
Aerial prevalence of Aspergillus calidoustus isolates in and around a tertiary care hospital in Kuwait and assessment of their pathogenicity. J Clin Microbiol (2014) 0.75
Discovery of Aspergillus frankstonensis sp. nov. during environmental sampling for animal and human fungal pathogens. PLoS One (2017) 0.75
Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 11.12
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med (2008) 4.68
In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med (2013) 3.72
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2005) 3.41
Multiple-triazole-resistant aspergillosis. N Engl J Med (2007) 3.33
Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis (2005) 3.14
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis (2009) 3.03
Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA (2007) 3.03
Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med (2014) 2.95
EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect (2012) 2.86
Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur Heart J (2004) 2.85
Continuous aspiration of subglottic secretions in the prevention of ventilator-associated pneumonia in the postoperative period of major heart surgery. Chest (2008) 2.78
Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother (2006) 2.76
Nocardiosis at the turn of the century. Medicine (Baltimore) (2009) 2.55
Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis (2009) 2.54
A randomized and prospective study of 3 procedures for the diagnosis of catheter-related bloodstream infection without catheter withdrawal. Clin Infect Dis (2007) 2.47
Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother (2009) 2.41
Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother (2008) 2.41
Direct E-test (AB Biodisk) of respiratory samples improves antimicrobial use in ventilator-associated pneumonia. Clin Infect Dis (2007) 2.33
Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis (2005) 2.27
Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species. Antimicrob Agents Chemother (2002) 2.26
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother (2008) 2.17
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother (2008) 2.11
Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr (2004) 2.11
Transmission of HIV-1 from an obstetrician to a patient during a caesarean section. AIDS (2006) 2.06
Fungal cell gigantism during mammalian infection. PLoS Pathog (2010) 2.04
Is the volume of blood cultured still a significant factor in the diagnosis of bloodstream infections? J Clin Microbiol (2007) 2.01
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 1.94
Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results. Clin Infect Dis (2004) 1.93
Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother (2005) 1.92
Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. J Clin Microbiol (2003) 1.90
Ventilator-associated pneumonia after heart surgery: a prospective analysis and the value of surveillance. Crit Care Med (2003) 1.88
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother (2003) 1.85
Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis (2009) 1.83
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother (2010) 1.82
Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis (2004) 1.81
Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2006) 1.81
Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis (2014) 1.73
Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med (2007) 1.69
Prevalence of BK virus replication among recipients of solid organ transplants. Clin Infect Dis (2005) 1.66
Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS (2006) 1.65
The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transpl (2009) 1.65
Song diversity predicts the viability of fragmented bird populations. PLoS One (2008) 1.63
Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis (2009) 1.62
Whole genome sequencing analysis of intrapatient microevolution in Mycobacterium tuberculosis: potential impact on the inference of tuberculosis transmission. J Infect Dis (2013) 1.61
Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol (2009) 1.61
Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003). Enferm Infecc Microbiol Clin (2006) 1.59
Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet (2004) 1.59
Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis (2008) 1.58
Immune response to fungal infections. Vet Immunol Immunopathol (2008) 1.58
Pre-emptive broad-spectrum treatment for ventilator-associated pneumonia in high-risk patients. Intensive Care Med (2013) 1.56
Non-HACEK gram-negative bacillus endocarditis. Ann Intern Med (2007) 1.56
Polyclonal and compartmentalized infection by Mycobacterium tuberculosis in patients with both respiratory and extrarespiratory involvement. J Infect Dis (2003) 1.54
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med (2015) 1.54
A comparison of fluorescent in situ hybridization and multiplex short tandem repeat polymerase chain reaction for quantifying chimerism after stem cell transplantation. Haematologica (2005) 1.53
Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis (2008) 1.51
New real-time PCR able to detect in a single tube multiple rifampin resistance mutations and high-level isoniazid resistance mutations in Mycobacterium tuberculosis. J Clin Microbiol (2002) 1.50
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents (2008) 1.50
Invasive aspergillosis in the recipients of liver retransplantation. Liver Transpl (2006) 1.49
Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. J Clin Microbiol (2012) 1.49
Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother (2007) 1.48
Laboratory-acquired clostridium difficile polymerase chain reaction ribotype 027: a new risk for laboratory workers? Clin Infect Dis (2008) 1.48
[Guidelines for the treatment of Invasive Candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 Update]. Enferm Infecc Microbiol Clin (2011) 1.46
Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol (2011) 1.45
Characterization of clonal complexity in tuberculosis by mycobacterial interspersed repetitive unit-variable-number tandem repeat typing. J Clin Microbiol (2005) 1.45
Is Candida colonization of central vascular catheters in non-candidemic, non-neutropenic patients an indication for antifungals? Intensive Care Med (2009) 1.44
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol (2006) 1.43
Molecular diagnosis of infective endocarditis by real-time broad-range polymerase chain reaction (PCR) and sequencing directly from heart valve tissue. Medicine (Baltimore) (2007) 1.41
In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother (2003) 1.40
Retracted An island paradigm on the mainland: host population fragmentation impairs the community of avian pathogens. Proc Biol Sci (2011) 1.40
Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob Agents Chemother (2011) 1.39
Campylobacter bacteremia: clinical characteristics, incidence, and outcome over 23 years. Medicine (Baltimore) (2010) 1.39
Etherification of biodiesel-derived glycerol with ethanol for fuel formulation over sulfonic modified catalysts. Bioresour Technol (2011) 1.39
Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother (2008) 1.37
Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis (2009) 1.37
Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol (2011) 1.35
Rapid direct detection of multiple rifampin and isoniazid resistance mutations in Mycobacterium tuberculosis in respiratory samples by real-time PCR. Antimicrob Agents Chemother (2004) 1.34
The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther (2007) 1.33
Transient fungemia caused by an amphotericin B-resistant isolate of Candida haemulonii. J Clin Microbiol (2002) 1.30
Analysis of changes in recent tuberculosis transmission patterns after a sharp increase in immigration. J Clin Microbiol (2006) 1.29
Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS One (2011) 1.29
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob Agents Chemother (2009) 1.28
G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob Agents Chemother (2003) 1.28